| Literature DB >> 33737188 |
Xiao Lin Huang1, Muhammad Imran Khan2, Jing Wang3, Rizwan Ali4, Syed Wajahat Ali4, Qurat-Ul-Ain Zahra4, Ahsan Kazmi5, Arbelo Lolai1, Yu Lin Huang1, Alamdar Hussain6, Muhammad Bilal7, Fenfen Li8, Bensheng Qiu9.
Abstract
In the past two decades, significant progress has been made in the past two decades towards the understanding of the basic mechanisms underlying cancer growth and angiogenesis. In this context, receptor tyrosine kinases (RTKs) play a pivotal role in cell proliferation, differentiation, growth, motility, invasion, and angiogenesis, all of which contribute to tumor growth and progression. Mutations in RTKs lead to abnormal signal transductions in several pathways such as Ras-Raf, MEK-MAPK, PI3K-AKT and mTOR pathways, affecting a wide range of biological functions including cell proliferation, survival, migration and vascular permeability. Increasing evidence demonstrates that multiple kinases are involved in angiogenesis including RTKs such as vascular endothelial growth factor, platelet derived growth factor, epidermal growth factor, insulin-like growth factor-1, macrophage colony-stimulating factor, nerve growth factor, fibroblast growth factor, Hepatocyte Growth factor, Tie 1 & 2, Tek, Flt-3, Flt-4 and Eph receptors. Overactivation of RTKs and its downstream regulation is implicated in tumor initiation and angiogenesis, representing one of the hallmarks of cancer. This review discusses the role of RTKs, PI3K, and mTOR, their involvement, and their implication in pro-oncogenic cellular processes and angiogenesis with effective approaches and newly approved drugs to inhibit their unrestrained action.Entities:
Keywords: Angiogenesis; Cancer therapies; Receptor tyrosine kinase signaling; Tumor growth
Year: 2021 PMID: 33737188 DOI: 10.1016/j.ijbiomac.2021.03.075
Source DB: PubMed Journal: Int J Biol Macromol ISSN: 0141-8130 Impact factor: 6.953